FDA Announces Nationwide Cetirizine Recall After Cross-Contamination with Ranitidine Discovered
Key Insights
Unique Pharmaceutical Laboratories voluntarily recalled four lots of 5 mg cetirizine hydrochloride tablets after a pharmacy technician discovered red dots and discoloration on tablets, later identified as ranitidine contamination.
The affected lots (GY825029–GY825032) carry an October 2028 expiration date and were distributed nationwide through wholesalers and pharmacies via Rising Pharma Holdings (search).
For individuals with ranitidine sensitivity, accidental ingestion could trigger severe hypersensitivity reactions including anaphylaxis (search), though no adverse events have been reported to date.
A nationwide recall of generic cetirizine hydrochloride tablets is underway after federal regulators confirmed that bottles of the common allergy medication were cross-contaminated with ranitidine, a heartburn drug with a troubled regulatory history. Unique Pharmaceutical Laboratories, a division of India-based J.B. Chemicals & Pharmaceuticals Ltd., voluntarily pulled four lots of 5 mg cetirizine hydrochloride tablets following a discovery made by an alert pharmacy technician.
The technician noticed something unusual while counting tablets before dispensing them to a customer: some pills bore an odd red dot, while others were visibly discolored with multiple reddish spots. Subsequent investigation determined the contaminant to be ranitidine, the once-ubiquitous stomach acid reducer formerly sold under the brand name Zantac. Ranitidine was pulled from U.S. shelves in 2020 after regulators found it could break down into NDMA, a probable human carcinogen, and only returned to market last year in a reformulated version.
Scope of the Recall
The recall is narrow in terms of lot numbers but broad in geographic reach. Affected products are 100-count HDPE bottles of 5 mg cetirizine hydrochloride tablets under NDC 16571-401-10, distributed nationally through wholesalers and pharmacies via Unique's U.S. partner, Rising Pharma Holdings (search). The four recalled lot numbers are GY825029, GY825030, GY825031, and GY825032, all carrying an October 2028 expiration date. The FDA published the recall announcement on July 20, with the company initiating the action on July 18.
Clinical Risk Assessment
For most cetirizine users, inadvertently swallowing a stray ranitidine tablet would likely cause little harm. However, the FDA warns that individuals with a known sensitivity to ranitidine or its ingredients face a significantly elevated risk. According to the recall announcement, ingesting contaminated tablets could trigger severe hypersensitivity reactions, including anaphylaxis (search)—a potentially life-threatening response involving a sudden drop in blood pressure, difficulty breathing, difficulty swallowing, swelling of the throat and face, widespread itching, hives, and loss of consciousness.
As of the announcement date, Unique Pharmaceuticals stated it has not received any adverse event reports tied to the recall.
Consumer Guidance
Consumers with cetirizine at home should check the lot number on their bottle against the recall list before taking another dose. A visual inspection of the tablets is also warranted; a red dot or blotchy discoloration on what should be a plain white pill is the telltale sign regulators are pointing to. If either matches, the FDA advises stopping use immediately.
Rising Pharma Holdings (search) has alerted its distributors and direct customers by email and is arranging for the return of all recalled products. Consumers with questions can contact Rising Pharma at 1-844-874-7464, Monday through Friday from 8 a.m. to 5 p.m. ET, or by emailing pv@risingpharma.com. Adverse reactions or quality concerns can also be reported directly to the FDA's MedWatch Adverse Event Reporting Program.
The recall comes during peak allergy season for much of the country, a timing that amplifies its practical impact on consumers who routinely purchase antihistamines in bulk. For now, the remedy is straightforward: check the lot number, examine the pills, and when in doubt, discard the bottle and obtain a replacement.